Send to

Choose Destination
Radiol Clin North Am. 2008 Mar;46(2):199-211, vii. doi: 10.1016/j.rcl.2008.03.004.

The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.

Author information

Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center/Nuclear Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-6948, USA.


Fully diagnostic positron emission tomography (PET)/CT scans acquired during oral and intravenous contrast can be provided to patients and referring physicians in a single imaging session. Although FDG uptake varies, most low-grade lymphomas exhibit sufficient FDG avidity to also be staged reliably with FDG PET/CT. PET/CT imaging is more accurate for lymphoma staging than PET or CT alone and has substantial impact on patient management. This accurate whole-body glucose metabolic survey should serve as the baseline for subsequent treatment response evaluations. PET/CT has evolved to become the modality of choice for staging of nodal and extranodal lymphoma, for assessing therapeutic response, and for establishing patient prognosis.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center